Kbc Group Nv Charles River Laboratories International, Inc. Transaction History

Kbc Group Nv

$36.3 Billion
Q4 2024

A detailed history of Kbc Group Nv transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 85,362 shares of CRL stock, worth $14.3 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

85,362

Previous 84,566 0.94%

Holding current value

$14.3 Million

Previous $16.7 Million 5.4%

% of portfolio

0.04%

Previous 0.05%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 22, 2025	BUY	$178.58 - $220.69 $142,149 - $175,669	796 Added 0.94%	85,362 $15.8 Million
Q3 2024 Nov 06, 2024	SELL	$187.96 - $245.29 $9.46 Million - $12.3 Million	-50,319 Reduced 37.31%	84,566 $16.7 Million
Q2 2024 Jul 17, 2024	SELL	$206.39 - $268.73 $152,934 - $199,128	-741 Reduced 0.55%	134,885 $27.9 Million
Q1 2024 May 08, 2024	SELL	$203.52 - $273.43 $16.3 Million - $21.9 Million	-80,013 Reduced 37.11%	135,626 $36.7 Million
Q4 2023 Feb 13, 2024	BUY	$164.52 - $238.84 $34.8 Million - $50.5 Million	211,414 Added 5003.88%	215,639 $51 Million
Q3 2023 Feb 15, 2024	BUY	$194.44 - $217.61 $41.5 Million - $46.4 Million	213,341 Added 4124.13%	218,514 $42.8 Million
Q2 2023 Feb 15, 2024	BUY	$183.71 - $210.25 $366,501 - $419,448	1,995 Added 62.78%	5,173 $1.09 Million
Q2 2023 Jul 28, 2023	SELL	$183.71 - $210.25 $13,227 - $15,138	-72 Reduced 1.68%	4,225 $888,000
Q1 2023 Feb 14, 2024	SELL	$191.89 - $259.92 $333,504 - $451,740	-1,738 Reduced 25.44%	5,093 $1.03 Million
Q1 2023 May 04, 2023	BUY	$191.89 - $259.92 $228,349 - $309,304	1,190 Added 38.3%	4,297 $867,000
Q4 2022 Feb 14, 2024	BUY	$197.11 - $250.07 $716,297 - $908,754	3,634 Added 113.67%	6,831 $1.49 Million
Q3 2022 Feb 15, 2024	SELL	$182.44 - $250.54 $38.8 Million - $53.2 Million	-212,461 Reduced 98.53%	3,178 $625,000
Q2 2022 Feb 14, 2024	BUY	$204.13 - $302.4 $45,929 - $68,040	225 Added 7.57%	3,197 $684,000
Q2 2022 Jul 26, 2022	BUY	$204.13 - $302.4 $27,557 - $40,824	135 Added 4.54%	3,107 $665,000
Q1 2022 Feb 14, 2024	SELL	$255.51 - $362.11 $16.6 Million - $23.5 Million	-65,014 Reduced 95.63%	2,972 $844,000
Q1 2022 May 06, 2022	SELL	$255.51 - $362.11 $16.6 Million - $23.5 Million	-65,014 Reduced 95.63%	2,972 $844,000
Q4 2021 Feb 14, 2024	SELL	$351.38 - $448.68 $51.9 Million - $66.2 Million	-147,653 Reduced 68.47%	67,986 $25.6 Million
Q4 2021 Feb 03, 2022	SELL	$351.38 - $448.68 $931,157 - $1.19 Million	-2,650 Reduced 3.75%	67,986 $25.6 Million
Q3 2021 Nov 10, 2021	BUY	$372.64 - $458.3 $23.3 Million - $28.7 Million	62,523 Added 770.65%	70,636 $29.1 Million
Q2 2021 Aug 11, 2021	BUY	$294.17 - $371.65 $2.39 Million - $3.02 Million	8,113 New	8,113 $3 Million

Others Institutions Holding CRL

# of Institutions

708

Shares Held

53.9M

Call Options Held

122K

Put Options Held

239K

View Full List

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Ticker CRL
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 50,863,300
Market Cap $8.54B
Description
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...

More about CRL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.

Account